January 3, 2017
[Press Release] Supreme Pharmaceuticals announces the closing of its $50 million bought deal private placement and concurrent $5 million non-brokered private placement for aggregate gross proceeds of $55 million.
Pursuant to the offering, the company issued a total of $55 million of 10% unsecured convertible debentures and 42,350,000 common share purchase warrants.
The company intends to use the net proceeds of the offering to expand the operating footprint of the company's Hybrid Greenhouse facility in Kincardine, Ontario and for general corporate and working capital purposes.
The syndicate for the Brokered Offering was led by Canaccord Genuity Corp. and included Dundee Securities Ltd., Beacon Securities Limited and Cormark Securities Inc.
All securities issued in the Offering are subject to a statutory four month hold period in accordance with Canadian securities law.
Pursuant to the offering, the company issued a total of $55 million of 10% unsecured convertible debentures and 42,350,000 common share purchase warrants.
The company intends to use the net proceeds of the offering to expand the operating footprint of the company's Hybrid Greenhouse facility in Kincardine, Ontario and for general corporate and working capital purposes.
The syndicate for the Brokered Offering was led by Canaccord Genuity Corp. and included Dundee Securities Ltd., Beacon Securities Limited and Cormark Securities Inc.
All securities issued in the Offering are subject to a statutory four month hold period in accordance with Canadian securities law.
